Understanding AI: The Technology, the Infrastructure and the Money
Vidya Bala
October 22, 2026
Read More »
Prime Stock recommendation : A preferred partner for drug discovery outsourcing
PrimeInvestor is now a SEBI-registered Portfolio Management Service (minimum investment ₹50 lakh). We no longer offer research subscriptions, stock or fund recommendations, or DIY advisory. This article is from our research archive (2020–2026) and is for information only. Explore PrimeInvestor PMS →
N V Chandrachoodamani
Chandrachoodamani started his capital market career in mid 2000s with Equity Intelligence India and then worked with several capital market Intermediaries in various roles over the last 15 years. Most of his career experience has been in equity research and PMS. Most recently, he was with MOAT, a PMS firm. He is a graduate in mathematics, a post graduate in finance, and holds a CFP certification. LinkedIn|Twitter
All Posts »
More like this
When stock markets return less than FDs, what should you do?
Vidya Bala
October 16, 2026
Read More »
2 thoughts on “Prime Stock recommendation : A preferred partner for drug discovery outsourcing”
Eventhough i upgraded to premium and paid still i cannot get to open the research for stock meant for premium subscriber.
please write the priviliges of premium subscribers as you mentioned earlier i upgraded.
When log in and go to stock for premium subsriber get comment please log in.eventhough access after log in.
Please get the error rectified or else refund my subscription.
Regards
krishnaraj
[email protected]
9821040598
Hello Sir,
We have raised a ticket and responded to your query. Kindly check your inbox for the same.
Regards,
Gaurav Menon
Comments are closed.